Gilead Sciences, Inc.
333 Lakeside Drive
Tel: 800-GILEAD-5 or 650-574-3000
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
CEO: John F. Milligan, PhD
Chief Scientific Officer: Norbert W. Bischofberger, PhD
CFO: Robin L. Washington
COO: Kevin Young
Please click here for clinical trial information.
1355 articles with Gilead Sciences, Inc.
European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Biktarvy®.
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
Ahead of next Monday’s U.S. Food and Drug Administration (FDA) committee review of Eli Lilly and Incyte’s baricitinib for rheumatoid arthritis, concerns over blood clots, may scuttle the drug’s chances.
4/13/2018Less than one week after licensing three non-alcoholic steatohepatitis (NASH) programs from Eli Lilly, startup company Terns Pharmaceuticals has strengthened its leadership team with the appointment of two scientific advisors.
Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
-- Combination Therapy Data Presented from First 12-Week Study -- -- Enrollment Complete for Phase 3 STELLAR Trials of ASK1 Inhibitor Selonsertib --
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Days after being tapped to helm the U.S. Centers for Disease Control and Prevention, Dr. Robert Redfield predicted the AIDs epidemic can be defeated within the next three to seven years and the challenges of the opioid crisis can also be brought “to its knees.”
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
The head of GlaxoSmithKline's pharmaceuticals division is pushing to cut its budget by 20 percent.
3/20/2018Gilead Sciences essentially created a cure for hepatitis C and may be well on its way to developing a cure for HIV-AIDS.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly's re-submission for their moderate-to-severe rheumatoid arthritis drug.
After serving nearly 30 years with the company Norbert Bischofberger is stepping down from his role as head of research and development and chief scientific officer of Gilead Sciences.
Gilead Sciences’ Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and Chief Scientific Officer, effective at the end of April 2018.